Ginkgo Bioworks Holdings (DNA) Income from Non-Controlling Interests (2020 - 2022)
Ginkgo Bioworks Holdings posted quarterly Income from Non-Controlling Interests of $2.4 million for Q4 2022, up 155.08% year-on-year from $936954.3 in Q4 2021, and up 236.96% on a QoQ basis from -$1.7 million in Q2 2022.
Ginkgo Bioworks Holdings (DNA) has 3 years of Income from Non-Controlling Interests data on file, last reported at $2.4 million in Q4 2022.
- For the quarter ending Q4 2022, Income from Non-Controlling Interests rose 155.08% year-over-year to $2.4 million; the trailing twelve-month figure through Sep 2023 stood at $2.4 million (up 129.25% YoY), and the FY2022 full-year result was -$1.4 million, up 78.12% from the prior year.
- Income from Non-Controlling Interests for Q4 2022 stood at $2.4 million, up from -$1.7 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $2.4 million in Q4 2022 and bottomed at -$4.3 million in Q4 2021.
- The 3-year median for Income from Non-Controlling Interests is -$753000.0 (2020), against an average of -$968888.9.
- The widest annual swing landed in 2021, when Income from Non-Controlling Interests sank 838.03%; it then surged 155.08% in 2022.
- A 3-year view of Income from Non-Controlling Interests shows it stood at -$753000.0 in 2020, then slumped by 476.23% to -$4.3 million in 2021, then soared by 155.08% to $2.4 million in 2022.
- The last three Income from Non-Controlling Interests figures came in at $2.4 million (Q4 2022), -$1.7 million (Q2 2022), and -$2.1 million (Q1 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 2.39 Mn |
| Jun 30, 2022 | -1.75 Mn |
| Mar 31, 2022 | -2.09 Mn |
| Dec 31, 2021 | -4.34 Mn |
| Sep 30, 2021 | -524,000.00 |
| Jun 30, 2021 | -523,000.00 |
| Mar 31, 2021 | -1.21 Mn |
| Dec 31, 2020 | -753,000.00 |
| Sep 30, 2020 | 71,000.00 |